Drug Profile
Research programme: polypeptide conjugated interleukin-1 receptor antagonist - Aravive
Alternative Names: VRS-826Latest Information Update: 10 Feb 2022
Price :
$50
*
At a glance
- Originator Amunix
- Developer Versartis
- Class Peptides; Recombinant fusion proteins
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 08 Feb 2022 Amunix has been acquired by Sanofi
- 15 Oct 2018 Versartis has merged with Aravive Biologics to form Aravive
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (SC, Injection)